Identifying and characterizing the molecular fingerprint for tumor cell is important as it can implicate with respect to diagnosis, prognosis, or treatment plans for each individual.
Indeed, Whole genome sequencing (WGS) or Whole exome sequencing (WES) can provide the most comprehensive data about genomic profiles of cancer cells, but the major drawback is that both have high sequencing and analysis cost due to the large target area. As a result, there has been a growing interest in recent years in large-sized comprehensive panels that can assess multiple types of cancer. In response to this demand, Celemics has developed and launched CancerScreen Comprehensive panel.
The CancerScreen Comprehensive panel consists total of 765 genes enabling highly accurate and comprehensive analysis for identifying significant mutations and variants for solid tumors. The panel is designed to detect all types of variants, including SNV, Indel, CNV, rearrangements, microsatellite instability (MSI), immuno-oncology markers, and other possible relevant variants which are crucial biomarkers for cancer immunotherapy. It is also designed to detect EBV (Epstein-Barr virus) and HPV (Human Papillomavirus), which are known to be associated with cancer development.
Recently, various manufacturers, such as Company T and Company I, have also released comprehensive cancer panels. Compared to other competing products, Celemics CancerScreen Comprehensive panel offers the advantage of targeting the greatest number of genes and cancer-associated illnesses. This will eliminate the needs for additional tests beyond this panel. With Celemics’ exclusive probe design and assay optimization technologies, the panel ensures superior performance in terms of detection sensitivity and specificity, enabling time-saving and cost-effective NGS in various oncology-related applications.
Along with the panels and reagents, Celemics also offers client-specific full bioinformatics support, with the the report consists of primary, secondary, and tertiary anlaysis for in-depth understanding and interpretation of sequencing data.
As illustrated below, Celemics’ CancerScreen Comprehensive panel can and will be able to detect all the cancer-associated variants, even the ones located in hard-to-capture regions or with low VAF. Celemics offers flexible customization of the ready-to-use panels; if the gene of interest does not exist in the panel or if you wish to expand the target region of interest, it can be added separately through our gene add-on service. All Celemics designed and manufactured panels can be integrated on to various sequencing platforms, such as Illumina, Ion Torrent, and MGI by our proprietary blocker and assay optimization technology.
Figure A&B. Expected vs. Detected VAF correlation and list of variants for AF comparison.
Celemics offers flexible customization of the ready-to-use panels; if the gene of interest does not exist in the panel or if you wish to expand the target region of interest, it can be added separately through our gene add-on service. All Celemics designed and manufactured panels can be integrated on to various sequencing platforms, such as Illumina, Ion Torrent, and MGI by our proprietary blocker and assay optimization technology.
Explore the Celemics’ Extensive Portfolio of NGS-based Solutions for Oncology > View Detail